Description
| Product Name: | Anti-Human TNF alpha (Adalimumab) |
| SKU: | IVMB0425 |
| Size: | 50 µg, 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | D2E7 |
| Target: | TNF alpha |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha |
| Product Concentration: | 0.5 mg/ml |
| Immunogen: | Human TNF alpha |
| Applications and Recommended Usage: | FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
| Antigen Distribution: | TNF-α is secreted by macrophages, monocytes, neutrophils, T cells, B cells, NK cells, LAK cells. |
| Formulation: | This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Adalimumab. Clone D2E7 binds to soluble TNF- α, but not to TNF- β (lymphotoxin). This product is for research use only. |
| Additional Applications Reported In Literature: | ELISAFA |
| Additional Reported Applications For Relevant Conjugates: | BNIP |
Adalimumab is a research-grade monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNF-α). TNF-α is a 17.5 kD protein that mediates inflammation and immunity caused by the invasion of viruses, bacteria, and parasites by initiating a cascade of cytokines that increase vascular permeability, thus bringing macrophages and neutrophils to the site of infection. TNF-α secreted by the macrophage causes the blood to clot which provides containment of the infection. TNF-α inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis, and juvenile idiopathic arthritis. Adalimumab blocks the interaction with the p55 and p75 cell surface TNF receptors thus, neutralizing the biological function of TNF. Anti-Human TNF alpha (Adalimumab) utilizes the same variable regions from the therapeutic antibody Adalimumab making it ideal for research projects.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This biotinylated antibody is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
